CYTK Key Statistics, Chart & Performance
The current stock price of CYTK is 64.18 USD. In the past month the price decreased by -4.99%. In the past year, price increased by 35.52%.
CYTK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.33 | 406.30B | ||
| AMGN | AMGEN INC | 15.27 | 179.83B | ||
| GILD | GILEAD SCIENCES INC | 15.34 | 155.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.67 | 117.47B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.41 | 82.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.67 | 52.94B | ||
| INSM | INSMED INC | N/A | 37.84B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.53 | 25.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.5 | 22.16B | ||
| INCY | INCYTE CORP | 15.64 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About CYTK
Company Profile
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The company is headquartered in South San Francisco, California and currently employs 498 full-time employees. The company went IPO on 2004-04-29. The firm is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The firm is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
Company Info
CYTOKINETICS INC
350 Oyster Point Boulevard
South San Francisco CALIFORNIA 94080 US
CEO: Robert I. Blum
Employees: 498
Phone: 16506243000
CYTOKINETICS INC / CYTK FAQ
What does CYTK do?
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The company is headquartered in South San Francisco, California and currently employs 498 full-time employees. The company went IPO on 2004-04-29. The firm is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The firm is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
What is the stock price of CYTOKINETICS INC today?
The current stock price of CYTK is 64.18 USD. The price increased by 1.41% in the last trading session.
What is the dividend status of CYTOKINETICS INC?
CYTK does not pay a dividend.
How is the ChartMill rating for CYTOKINETICS INC?
CYTK has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists CYTK stock?
CYTK stock is listed on the Nasdaq exchange.
Is CYTOKINETICS INC (CYTK) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CYTK.
What is the expected growth for CYTK stock?
The Revenue of CYTOKINETICS INC (CYTK) is expected to grow by 2490.49% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
CYTK Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CYTK. When comparing the yearly performance of all stocks, CYTK is one of the better performing stocks in the market, outperforming 89.01% of all stocks.
CYTK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CYTK. Both the profitability and financial health of CYTK have multiple concerns.
CYTK Financial Highlights
Over the last trailing twelve months CYTK reported a non-GAAP Earnings per Share(EPS) of -6.32. The EPS decreased by -17.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52.34% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CYTK Forecast & Estimates
26 analysts have analysed CYTK and the average price target is 81.15 USD. This implies a price increase of 26.44% is expected in the next year compared to the current price of 64.18.
For the next year, analysts expect an EPS growth of -23.14% and a revenue growth 2490.49% for CYTK